Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | ||
| Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | ||
| Vabysmo | faricimab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 3, 2024